NCT06435429Phase 3Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-04-28Estimated

Enrollment · participants550Estimated

Source updated2026-02-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-10 · 1 field changed

Primary completion date changed

− Before

~~26 Sep 2028~~

+ After

28 Apr 2028

Check registry source

Study details

Conditions studied

Metastatic HER2-positive Breast Cancer

Treatments or interventions studied

ZanidatamabDrug
TrastuzumabDrug
EribulinDrug
VinorelbineDrug
GemcitabineDrug
CapecitabineDrug

Primary outcomes · main study measures

Read the study measures

measure: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR); description: PFS is defined as the time in months from randomization to the date of first documented disease progression (as assessed by BICR according to RECIST v1.1) or death from any cause, whichever occurs first.; timeFrame: Until disease progression or death, up to approximately 44 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history